Free Newsletter
Chimp virus plays key role in malaria vaccine
A new blend of a genetically modified chimp adenovirus and a malaria gene is proving promising as a potential vaccine against malaria. The adenovirus is used to spur an immune response against malaria, a disease that claims a host of lives each year. By turning to a chimp adenovirus the Oxford University scientists say they can avoid the immunity built up in people against human adenoviruses. Governments set out in 2000 to halve the death rate from malaria by 2010, but there's little hope of reaching that goal without an effective vaccine. The Oxford team says that they believe that they could be within five years of a new vaccine.
- read the article from the BBC
Related Articles:
Sanaria takes new approach for malaria vaccine. Report
New malaria vaccine offers better protection. Report
Gates Foundation readies $258M for new malaria programs. Report
New tech drives huge growth in vaccine business. Report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
